Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases | Zendy

Stefan Stremitzer | Zendy; Peter Vermeulen | Zendy; Shan Graver | Zendy; Mark Kockx | Zendy; Luc Dirix | Zendy; Dongyun Yang | Zendy; Wu Zhang | Zendy; Judith Stift | Zendy; Friedrich Wrba | Zendy; Thomas Gruenberger | Zendy; HeinzJosef Lenz | Zendy; Stefan Scherer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases

Author(s) -

Stefan Stremitzer,

Peter Vermeulen,

Shan Graver,

Mark Kockx,

Luc Dirix,

Dongyun Yang,

Wu Zhang,

Judith Stift,

Friedrich Wrba,

Thomas Gruenberger,

HeinzJosef Lenz,

Stefan Scherer

Publication year - 2020

Publication title -

british journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.833

H-Index - 236

eISSN - 1532-1827

pISSN - 0007-0920

DOI - 10.1038/s41416-020-0812-z

Subject(s) - medicine , bevacizumab , colorectal cancer , perioperative , chemotherapy , immune system , gastroenterology , immunohistochemistry , oncology , pathology , cancer , surgery , immunology

Patients with desmoplastic (angiogenic) histopathological growth pattern (HGP) colorectal liver metastases (CLM) might derive more benefit from bevacizumab-based chemotherapy than those with replacement (non-angiogenic) HGP. This study investigated the association of HGP with the immune phenotype (IP) and clinical outcome after liver resection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research